Autolus Therapeutics PLC 10-Q quarterly reports

Autolus Therapeutics plc announced significant revenue growth in the second quarter of 2026, primarily driven by increased sales of its AUCATZYL therapy in the US and UK.

Autolus Therapeutics plc announced its first-quarter 2026 financial results, highlighting significant growth in product revenue from AUCATZYL and providing updates on its clinical pipeline.

Autolus Therapeutics reports significant product revenue from AUCATZYL in Q3 2025, alongside ongoing clinical advancements and strategic market expansion efforts.

Autolus Therapeutics reports initial US product revenue for AUCATZYL but faces significant commercialization hurdles in Europe and increased net losses.

Autolus Therapeutics announces its Q1 2025 financial results, marking the first commercial sales of AUCATZYL and providing updates on its clinical programs.

Autolus Therapeutics announced FDA approval for AUCATZYL and provided a financial update for the third quarter of 2024, highlighting increased operating expenses and a net loss.

Autolus Therapeutics reports a net loss of $58.3 million for the second quarter of 2024, alongside significant advancements in their clinical programs and a strengthened financial position.

Autolus Therapeutics provides a first-quarter update highlighting the acceptance of its obe-cel marketing application by the EMA, a new manufacturing authorization, and significant financial activities.